Wnt/b-catenin signalling is crucial for maintaining the balance between cell proliferation and differentiation, both during tissue morphogenesis and during tissue maintenance in postnatal life. Whereas the signalling activities of the core Wnt/b-catenin pathway components are understood in great detail, far less is known about the precise role and regulation of the many different modulators of Wnt/b-catenin signalling that have been identified to date.
Introduction
Wnt/b-catenin signalling is crucial for embryonic development and tissue homeostasis in all multicellular animals. In mammals, it is first required for induction of the primitive streak at the onset of gastrulation . It continues to help control cell proliferation and differentiation at different anatomical sites during all subsequent steps of tissue morphogenesis and throughout postnatal life. At the molecular level, Wnt/bcatenin signalling promotes the formation of CTNNB1/TCF complexes, in which b-catenin (CTNNB1) functions as a co-activator for transcription factors of the TCF/LEF family to modulate gene expression in a tissue-specific fashion.
The dynamic expression of 19 different WNT proteins results in a complex signalling landscape , with Wnt/b-catenin signalling being just one possible outcome. Secreted WNT proteins can interact with a variety of receptors and co-receptors at the cell surface, including FZD1-10, LRP5/6, RYK and ROR1/2 . Different combinations result in alternative, context-dependent biochemical responses. Just how these specific cellular responses are induced, both upstream at the level of ligand and receptor binding and downstream at the level of intracellular signal transduction, remains an area of active investigation . Under physiological conditions, activity of the Wnt/b-catenin pathway is tightly controlled. A so-called 'destruction complex', containing AXIN1, APC and GSK3, continuously binds and phosphorylates free CTNNB1. Because phosphorylated CTNNB1 is rapidly degraded by the proteasome, this ensures that low levels of cytoplasmic and nuclear CTNNB1 are maintained in the absence of a WNT signal. When WNT proteins engage FZD/LRP at the cell surface, the destruction complex is inactivated, resulting in an increase in the nucleocytoplasmic levels of CTNNB1 and the concomitant induction of CTNNB1/TCF transcriptional activity .
FRAT/GBP proteins are potent activators of CTNNB1/TCF signalling independent from WNT/FZD activity due to their capacity to bind GSK3 (van Amerongen et al., 2004; . FRAT1 and AXIN1 compete for the same binding site on GSK3B . Since the interaction between GSK3 and AXIN1 has been estimated to enhance the phosphorylation of CTNNB1 more than 20,000-fold , sequestration of GSK3 by FRAT thus increases CTNNB1/TCF signalling.
First identified as an oncogene in murine T-cell lymphoma progression , FRAT1 overexpression indeed correlates with the accumulation of CTNNB1 in a variety of human cancers . The Xenopus FRAT homologue, GBP, is critically required for dorsoventral axis formation as part of the maternal Wnt pathway . However, FRAT function is dispensable for Wnt/b-catenin signalling in mice , indicating that FRAT is a modulator, rather than a core component of the Wnt/b-catenin pathway in mammals. Moreover, the oncogenic activities of FRAT in lymphomagenesis may at least partially be GSK3 independent . To date, the precise role and regulation of FRAT1, and its close homologue FRAT2, remains to be resolved.
Here we identify TMEM98 as a novel FRAT-binding protein. We show that TMEM98 inhibits FRAT-induced CTNNB1/TCF signalling by reducing FRAT protein levels. We also demonstrate that TMEM98 traffics between multiple endosomal and membrane compartments. Together, these findings add a new layer of regulation for Wnt/b-catenin signalling and provide a potential molecular mechanism for the activities of TMEM98, mutations in which have been linked to autosomal dominant nanophthalmos .
Results

TMEM98 is a novel FRAT2-binding protein
To shed more light on FRAT protein function, we set out to identify new FRAT interactors. Focusing our efforts on FRAT2, we performed a yeast-two-hybrid assay using both full-length FRAT2 and an N-terminal deletion mutant containing the GSK3-binding site (FRAT2DN) as a bait. While we did not pick up GSK3 or any other known WNT pathway components in this screen, we did identify a number of putative novel FRAT2 binding proteins (Table 1 -2). One candidate, an unknown protein encoded by both the DKFZp564K1964 and ETVV536 transcripts, was picked up with high confidence in both the FRAT2 full-length and the FRAT2DN screen. We therefore decided to characterize this interaction in more detail.
Since performing these initial studies, the 226 amino-acid FRAT2-binding protein encoded by the DFKZp564K1964 and ETVV536 transcripts has officially become annotated as TMEM98, a putative transmembrane protein of unknown function. Similar to FRAT, TMEM98 is highly conserved among vertebrate species, but not present in invertebrates ( Supplementary Figure 1A, B) . The human and mouse homologues are more than 98% identical at the amino acid level, while the human and chick homologues are most divergent, with 73% of amino acid identity (Supplementary Figure 1C) . Table 1 Novel FRAT2-binding proteins identified in a yeast-two-hybrid screen with full-length FRAT2 as bait Putative interactors are listed in order of decreasing confidence (reflected in the PBS score).
Protein
Clone Name # clones PBS score Based on the sequence of the TMEM98 clones that were isolated in the original yeasttwo-hybrid screen, the FRAT2 binding domain of TMEM98 is located in the C-terminal half of the protein, with the longest clone spanning amino acids 66-226 and the shortest clone spanning amino acids 109-216 (Supplementary Figure 1C ). The fact that TMEM98 was identified in both the full-length FRAT2 and the FRAT2DN screen suggests that the TMEM98 binding domain of FRAT2 also resides in the Cterminus. By co-expressing myc-tagged FRAT2 and FLAG-tagged TMEM98 plasmid constructs, we were able to confirm binding of FRAT2 and full length TMEM98, but not an N-terminal deletion mutant lacking amino acids 1-34 (TMEM98DN), by co-immunoprecipitation from HEK293 cell lysates ( Figure 1A, B ). Western blot analysis revealed TMEM98DN to be unstable. Unlike full-length TMEM98, the deletion mutant can only be detected in the presence of the proteasome inhibitor MG132 ( Figure 1C ). Of note, co-expression of FRAT2 also stabilizes TMEM98DN ( Figure 1B ), suggesting that the two do interact, at least transiently, as a result of which at least some of the TMEM98DN escapes degradation.
TMEM98 membrane localization and topology
Because TMEM98 did not contain any known motifs or functional sites, we performed hydrophobicity analyses and subcellular localization predictions. All five secondary structure prediction algorithms used (HMMTOP; Phobius; TMHMM; TMpred; DAS-TMfilter) unanimously predict TMEM98 to have an N-terminal transmembrane domain spanning residues 6-25 (Table  3 , Supplementary Figure 1C) . A TMEM98-GFP fusion protein indeed localizes to the plasma membrane ( Figure 2A ), in addition to showing prominent localization to the Golgi and intracellular vesicles (Figure 2A, B ). Forward trafficking was inhibited by treatment of the cells with Brefeldin A, a reversible inhibitor of protein transport from the ER to the Golgi ( Figure 2C ), suggesting that TMEM98 is transported to the plasma membrane via the classical, secretory pathway. 
To test the requirement of the TMEM98 Nterminus for localization, we compared the expression of TMEM98 and TMEM98DN. Whereas full-length TMEM98 localizes to the Golgi and the plasma membrane, TMEM98DN shows diffuse expression throughout the cytoplasm at much lower levels ( Figure 2D ), in agreement with its rapid turnover by the proteasome ( Figure 1C ). Further support for a role of the TMEM98 N-terminus in subcellular targeting comes from the fact that an Nterminally tagged version of TMEM98 (GFP-ORF) becomes trapped in the ER, in contrast to a C-terminal fusion protein (ORF-GFP) that properly traffics to the Golgi and the cell membrane (Supplementary Figure 3, (Bannasch et al., 2004; ). Finally, the first 34 amino acids by themselves (TM1) are sufficient to target a fluorescent protein to the ER ( Figure  2E ). Together, these results demonstrate that the N-terminus of TMEM98 is both necessary and sufficient for targeting to the secretory pathway.
Although these results establish that TMEM98 contains an N-terminal transmembrane domain, prediction algorithms and the published literature do not agree on its exact topology or subcellular localization. Two out of five secondary structure prediction algorithms propose the presence of a putative N-terminal signal peptide (TMHMM; DAS-TMfilter, Table 3 ), but only one signal peptide prediction algorithm also estimates this sequence to be cleaved (PrediSi , Table 4 ). Four out of five algorithms (HMMTOP; Phobius; TMHMM; TMpred) predict TMEM98 to be a single pass type I protein (Table 3 ). In contrast, an experimental study reported TMEM98 to be a single pass type II protein, which was also found to be secreted in its full-length form . To resolve this apparent discrepancy, we first determined whether the Cterminus of TMEM98 is located extracellularly or intracellularly ( Figure 2F ). To this end, we generated a stable cell line expressing a doxycycline inducible TMEM98-FLAG protein ( Figure 2G ) and stained these cells with an anti-FLAG antibody under both unpermeabilized and permeabilized conditions. Subsequent FACS analysis revealed a clear signal for doxycycline-induced cells in both ( Figure 2H , Supplementary Figure 4 ), thus confirming that the TMEM98 C-terminus is, at least partially, located on the extracellular side of the plasma membrane. Staining with anti-Golgin97 antibody (middle) shows that TMEM98-AcGFP localizes to the Golgi apparatus (right, overlay). Nuclei are stained with DAPI and are shown in blue. Note that membrane localization is less prominent in this case because the Golgi apparatus is located in a different, more apical focal plane. (C) Pseudo-coloured confocal microscopy images of fixed HEK293A cells transiently transfected with TMEM98-AcGFP, showing that TMEM98 travels to the plasma membrane via the secretory route. Cells were treated with Brefeldin A for 4 hours to block forward trafficking through the Golgi, after which they were released. Cells were fixed at 0, 30, 60 and 180 minutes following release. Representative examples are shown. After 60 minutes, TMEM98-AcGFP reappears in the Golgi and after 180 minutes some signal can again be detected at the plasma membrane (arrowheads). (D) Pseudo-coloured confocal microscopy images of fixed HEK293A cells transiently transfected with TMEM98-AcGFP (left) or TMEM98DN-AcGFP, a deletion mutant lacking the first 34 amino acids (right). TMEM98DN-AcGFP localizes throughout the cell at much lower levels than the full length fusion protein (individual cells are indicated by arrowheads).
(E) Pseudo-coloured confocal microscopy images of fixed 293A cells transiently transfected with a fusion construct in which AcGFP was tagged with the first 34 amino acids of TMEM98 (TM1-AcGFP, left), showing that TM1 is sufficient for targeting to the ER, including distal protrusions at ER membrane contact sites (arrowheads). In contrast, an untagged fluorescent protein diffuses throughout the cytoplasm and nucleus as a free cytosolic protein (AcGFP, right).
(F) Schematic depicting the orientation of a single-pass type I (left) or type II (right) transmembrane protein.
(G) Western blot showing doxycycline dependent induction of TMEM98-FLAG in HEK293T cells stably transfected with tetO-TMEM98-FLAG and CMV-rtTA3.
(H) FACS analysis of the cells described in (G) in the absence (blue) and presence (red) of doxycycline (DOX) to induce TMEM98-FLAG expression. Following staining with an anti-FLAG antibody, TMEM98-FLAG can be detected in both unfixed, unpermeablized cells (left) and in fixed, permeabilized cells (right). The higher signal obtained in fixed, permeabilized cells likely reflects the large pool of TMEM98-FLAG present in the Golgi and intracellular vesicles, which is not detected by only staining the plasma membrane pool with an extracellularly exposed C-terminus.
TMEM98 is a negative regulator of Wnt/bcatenin signalling
We next investigated whether TMEM98 altered FRAT2 activity. To this end, we measured FRAT2 induced CTNNB1/TCF signalling in HEK293T cells using the wellknown TOPFLASH reporter assay. Cotransfection experiments showed that TMEM98 consistently reduced the level of CTNNB1/TCF signalling, induced by FRAT2, in a dosedependent manner ( Figure 3A ).
We next asked whether the observed effect was specific for FRAT2. To this end, we measured the effect of TMEM98 on the induction of CTNNB1/TCF signalling by both myc-FRAT1 and myc-FRAT2 ( Figure 3B ). Fulllength TMEM98 almost reverted FRAT2induced TOPFLASH reporter activity back to baseline (from 4.5 ± 1.8 to 1.1 ± 0.48 fold induction; mean ± standard deviation). When equal amounts of FRAT1 plasmid DNA were transfected, full-length TMEM98 reduced FRAT1-mediated TOPFLASH reporter activity to a similar extent (from 9.9 ± 6.1 to 3.3 ± 2.3 fold induction), equating to a 66% reduction for FRAT1 and a 76% reduction for FRAT2 on average. Indeed, myc-FRAT1 can also be coimmunoprecipitated with full length TMEM98-FLAG upon overexpression in HEK293T cells (Supplementary Figure 5A ). Thus, TMEM98 is capable of interacting with both FRAT homologues and blocks FRAT activity. However, FRAT1 is less capable of stabilizing TMEM98DN protein levels than FRAT2 (Supplementary Figure 5A, B ). We speculate that this is likely due to the fact that TMEM98 has a higher affinity for FRAT2 than for FRAT1.
TMEM98 reduces FRAT2 protein levels
To determine how TMEM98 inhibits the signalling activities of FRAT2, we first tested whether TMEM98 affected FRAT2 protein levels. To this end, we co-transfected a constant amount of myc-Frat2 plasmid DNA with increasing amounts of Tmem98-FLAG in HEK293T cells. These experiments revealed a dose-dependent reduction in FRAT2 protein levels in the presence of full length TMEM98 ( Figure 4A ). TMEM98 has a similar, but weaker effect on FRAT1 protein levels (Supplementary Figure 5C ). We repeated these experiments multiple times with differently tagged TMEM98 constructs (epitope-tagged TMEM98-FLAG, or fluorescent TMEM98-SGFP2 and TMEM98-mTq2 fusion proteins). Using quantitative Western blot analysis, we determined that TMEM98 caused up to a 48.2% ± 21.9% decrease (mean and standard deviation for n=6 independent experiments) in myc-FRAT2 protein levels ( Figure 4B , C).
To further substantiate that TMEM98 controls FRAT protein levels, we knocked down Tmem98 expression, reasoning that this should at least partially restore FRAT protein levels. Of the three RNAi constructs designed, two efficiently reduced both TMEM98 and TMEM98DN protein levels (Supplementary Figure 6 ). Western blot analysis showed that both FRAT1 and FRAT2 protein levels indeed increased when either Tmem98-FLAG or Tmem98DN-FLAG expression was knocked down ( Figure 4D ).
The RNAi constructs were designed to also recognize endogenous TMEM98 in HEK293T cells. Importantly, knocking down endogenous TMEM98 expression also resulted in an increase in FRAT1 and FRAT2 protein levels ( Figure 4D ). This translated to an increase in TOPFLASH reporter activity ( Figure  4E ), with our most efficient knockdown construct (TMEM98 RNAi #3) causing an average 1.7-fold and 1.6-fold increase in TOPFLASH induction by myc-FRAT1 (from 15.3 ± 8.1 to 26.7 ± 6.0) and myc-FRAT2 (from 5.4 ± 3.3 to 8.5 ± 3.1), respectively. When variation between individual experiments was accounted for ( Figure 4F ), knocking down endogenous TMEM98 boosted TOPFLASH reporter activity to 213% and 194% for myc-FRAT1 and myc-FRAT2, respectively. Together, these results confirm that TMEM98 indeed inhibits FRAT function by reducing FRAT2 and, to a lesser extent FRAT1, protein levels.
Figure 3
TMEM98 inhibits FRAT-induced CTNNB1/TCF signalling (A) Dual luciferase reporter assay in transiently transfected HEK293T cells to quantify the levels of CTNNB1/TCF signalling. Transfecting increasing amounts of Tmem98-FLAG cDNA with a constant amount of myc-Frat2 cDNA inhibits FRAT2 induced TCF/LEF (TOPFLASH) reporter activity. Graph depicts data from n=2-6 independent experiments for each condition, with each data point representing the average of three technical replicates. Boxes depict the spread of the data. Horizontal bars depict the median value. TOPFLASH luciferase values are normalized to CMV-Renilla, which was included as a transfection control. For each individual experiment the baseline TOPFLASH luciferase reporter activity in HEK293T cells transfected with empty vector (instead of myc-Frat2) was set to 1. (B) Same as in (A), but this time showing the effect of full-length TMEM98-Flag on myc-FRAT1 as well as myc-FRAT2. Note that FRAT1 is a more potent activator of CTNNB1/TCF signalling than FRAT2. Graph depicts data from n=5-7 independent experiments, with each data point representing the average of three technical replicates. Boxes depict the spread of the data. Horizontal bars depict the median value. Figure 5A , analysing the effects of TMEM98 on FRAT2 protein levels and vice versa. HSP90 serves as a loading control.
(C) Quantification of myc-FRAT2 protein levels upon co-transfecting increasing concentrations of TMEM98-sGFP2 or TMEM98-mTq2 fusion construct (FP=fluorescent protein), confirming that increasing concentrations of TMEM98 result in a reduction in myc-FRAT2 protein levels.. Graph depicts data from n=6 independent experiments. Boxes depict the spread of the data. Horizontal bars depict the median value. For each experiment, myc-FRAT2 protein levels in the absence of TMEM98 were set to 1.
(D) Western blot of lysates from transiently transfected HEK293T cells, showing that knocking down either endogenous (first three lanes) or transiently transfected TMEM98-FLAG (next three lanes) and TMEM98DN-FLAG (last three lanes) results in an increase in both myc-FRAT1 and myc-FRAT2 protein levels. pRS= pRetrosuper, the empty vector control for RNAi constructs #2 and #3. Endogenous GSK3b serves as a loading control. myc-FRAT1 TMEM98-FLAG TMEM98ΔN-FLAG RNAi
myc-FRAT2 TMEM98-FLAG TMEM98ΔN-FLAG RNAi 
FRAT2 affects TMEM98 protein levels
Despite our best efforts to carefully titrate the amounts of Tmem98-Flag DNA in our transfections, we frequently observed a nonlinear increase in TMEM98 protein levels when FRAT2 was co-transfected ( Supplementary  Figure 7 ). In addition, the TMEM98 mediated reduction in FRAT2 protein levels showed considerable variation between experiments depending on the absolute amounts and ratios of myc-Frat2 and Tmem98-Flag DNA that were transfected (Figure 4 , Supplementary Figure 7 and data not shown). Quantitative Western blot analysis confirmed that TMEM98 protein levels were consistently more variable in the presence of FRAT2, compared to when TMEM98 was transfected alone ( Figure 5A ). We hypothesized that this could be explained if TMEM98 not only controlled FRAT2 protein levels but if, in turn, FRAT2 somehow also affected TMEM98 levels.
To test this, we again co-transfected myc-Frat1 or myc-Frat2 with Tmem98-FLAG. This time, however, instead of varying the amounts of TMEM98, we kept the amount of Tmem98 DNA constant and transfected increasing amounts of Frat DNA. These experiments confirmed that FRAT2, rather than FRAT1, was able to increase TMEM98 protein levels (Supplementary Figure 7B , C). Taken together, our results demonstrate that TMEM98 inhibits FRAT2 and reduces its cytoplasmic protein levels, most likely as a result of a direct interaction. Conversely, FRAT2 stabilizes TMEM98. These findings are compatible with a model in which TMEM98 and FRAT2 form a negative feedback loop ( Figure 5B ). For FRAT1 these results are less consistent.
TMEM98 undergoes retrograde trafficking
A previous study showed TMEM98 to be secreted in its full-length form, presumably via exosomes . Whereas exosomes originate from multivesicular bodies (MVBs), our results suggest that TMEM98 reaches the plasma membrane via the classical secretory pathway (i.e. via the ER/Golgi, Figure 2 ).
However, when we analysed publicly available protein-protein interaction data using the BioGRID tool , we noticed an interaction between TMEM98 and multiple proteins that are associated with late (STX7, STX8, VT1B, VAMP8) and/or recycling endosomes (STX6, STX12, VAMP3). In addition, TMEM98 was also picked up in a yeast-two-hybrid screen as a binding partner of RABEPK, a Rab9 effector that is required for transport from endosomes to the trans-Golgi network . Although none of these interactions have been verified in living cells thus far, these findings suggest that TMEM98 may undergo retrograde trafficking Figure 8 ). Using confocal microscopy, we found that the TMEM98-GFP signal partially overlapped with that of the early endosome marker EEA1 ( Figure 6A ), a RAB5 effector and binding partner of STX6 . From this, we conclude that TMEM98 indeed enters the endocytic pathway.
To further follow its intracellular trafficking, we first tested whether TMEM98 reaches the lysosomal compartment. The signal of TMEM98-mTq2, which is still fluorescent at low intracellular pH (Goedhart et al., 2012) only occasionally overlapped with that of a lysosomal dye ( Figure 6B ). In addition, although TMEM98-positive vesicles were frequently found in close proximity to LAMP1-positive lysosomes, we were ultimately unable to confidently determine that the two indeed colocalized ( Figure 6C and data not shown). TMEM98-FLAG protein turnover was unchanged by the lysosomal inhibitor bafilomycin ( Supplementary Figure 9 ). Thus, we were unable to find conclusive evidence for either lysosomal targeting or degradation of TMEM98.
While performing these experiments, we noticed that many of the intracellular TMEM98positive structures had a more tubular appearance ( Figure 6D and other examples), which is in agreement with that of endosomal recycling domains . Indeed, we detected TMEM98-mTq2 in multiple endosomal compartments, as evidenced by its co-localization with RAB9A (involved in retrograde transport to the trans-Golgi network, Figure 6E ) and RAB7 (present on maturing and late endosomes, Figure 6F ). In addition, we found the TMEM98-GFP signal to also show partial overlap with that of the mannose-6-phosphate receptor (MPR), which is recycled to the trans-Golgi network from late endosomes in a RAB9-dependent manner ( Figure 6G ) . Together, our data suggest that TMEM98 traffics between multiple endosomal compartments, is recycled between the Golgi and the plasma membrane, but largely escapes lysosomal degradation.
Discussion
Wnt signal transduction is tightly controlled. Multiple agonists and antagonists modify activity of the Wnt/b-catenin pathway at the ligand and receptor level, with Dkks and Rspondins serving as prominent examples Szenker-Ravi et al., 2018) . However, Wnt-signalling strength can also be modulated intracellularly. For instance, expression of the negative feedback regulator Axin2 is induced in virtually all cells with active Wnt/b-catenin signalling Lustig et al., 2002) . This ensures reassociation of the destruction complex and dampening of the CTNNB1/TCF signalling response. FRAT proteins are positive regulators of the Wnt/b-catenin pathway. Their GSK3-binding activity allows initiation or amplification of the CTNNB1/TCF response even in the absence of a WNT stimulus. However, little remains known about their regulation at the molecular level or their precise physiological function.
Here we characterize TMEM98 as a novel negative regulator of FRAT and an inhibitor of FRAT-induced CTNNB1/TCF signalling. TMEM98 binds FRAT2, resulting in a reduction in FRAT2 protein levels and a concomitant decrease in FRAT2 signalling activity ( Figures  1, 3 and 4) . Conversely, FRAT2 can stabilize TMEM98 protein levels. As such, TMEM98 and FRAT2 constitute a dynamic regulatory switch with the capacity to fine-tune CTNNB1/TCF signalling activity ( Figure 5 ). Although TMEM98 also binds and inhibits FRAT1, the functional interaction between the two proteins is weaker. Whether this is due to the fact that FRAT1 has a shorter half-life and is expressed at lower levels than FRAT2 to begin with , or whether this represents an intrinsic difference in function, regulation or subcellular localization between FRAT1 and FRAT2, remains to be determined.
Our experiments largely agree with topology predictions and previous findings by confirming that TMEM98 localizes to the plasma membrane via an N-terminal membrane anchor (Figure 2 ). However, where most algorithms predict TMEM98 to be a single-pass type I transmembrane protein with an intracellular Cterminus, our results support the finding of Fu et al. that TMEM98 has an extracellular Cterminus . From our initial yeasttwo-hybrid screen we can conclude that amino acids 109-217 of TMEM98 interact with FRAT2 ( Supplementary Figure 2) . Given that FRAT2, as far as we know, is a soluble cytoplasmic protein, these findings raise an interesting conundrum: if TMEM98 indeed has an extracellular C-terminus, then where does it encounter and interact with FRAT? We present two possible scenarios (Figure 7) .
If TMEM98 is a single-pass type II protein with its entire C-terminus located extracellularly, logic dictates that the only intracellular location where interaction between TMEM98 and FRAT could take place would be inside early or late endosomes (Figure 7 , Model A), the contents of which are either recycled, targeted for lysosomal degradation or secreted in exosomes. Although neither FRAT1 nor FRAT2 have yet been shown to localize to the endosomal compartment, other WNT/b-catenin signalling components, including the FRAT binding protein GSK3 and the cell surface receptor Lgr5, have (Chairoungdua et al., 2010; Taelman et al., 2010) . Obviously, targeting of FRAT to either lysosomes or exosomes would result in a reduction of FRAT protein levels. However, we have so far not been able to find experimental support for either of these scenarios (data not shown).
Alternatively, the presence of a second transmembrane domain in TMEM98 would create and intracellular loop and potential binding site that would be capable of interacting with the cytoplasmic pool of FRAT (Figure 7 , Model B). Of note, the DAS-TMfilter algorithm indicates the presence of a second, more Cterminal, transmembrane domain (TM2, Figure  1A , Supplementary Figure 1C and Table 3 ) and, accordingly, predicts TMEM98 to be a dual pass transmembrane protein. Other algorithms (Phobius & TMpred) also detect this domain, but indicate it as non-significant. However, it should be noted that a previous study detected TMEM98 on the extracellular cell surface using an antibody with an epitope immediately downstream of the N-terminal transmembrane helix . This makes the existence of such an intracellular, cytoplasmic loop less likely.
Interestingly, the Xenopus FRAT homologue, GBP, has previously been found to bind to Kinesin light chain (KLC) and, as such, to be transported along microtubules during the process of cortical rotation in early frog embryogenesis . It is tempting to speculate that FRAT and TMEM98 could be similarly transported. Perhaps they are more broadly involved in endocytic trafficking in mammalian cells, which is also known to occur along microtubules in a kinesin-dependent manner . Of course, we cannot exclude other possibilities. Theoretically, TMEM98 can also exist in two different confirmations: a single pass type I and type II protein that could flip its orientation at the plasma membrane, as has been shown to occur upon changes in lipid composition . In conclusion, which, if any, of these models is correct and how this would ultimately result in a reduction in FRAT protein levels, remains to be tested.
Both FRAT and TMEM98 have been shown to have oncogenic activity . While the physiological role of FRAT proteins is still elusive , TMEM98 has been genetically linked to autosomal dominant nanophthalmos , a developmental disorder resulting in small eyes, hyperopia and an increased risk of angle closure glaucoma. In addition, TMEM98 was recently reported to bind to and prevent the self-cleavage of MYRF, an ER associated membrane-bound transcription factor . A molecular and cellular explanation for the involvement of TMEM98 in eye development and the onset of nanophthalmos is still missing. In future studies, it will be interesting to determine if and how the FRAT-binding and vesicular trafficking activities of TMEM98 contribute to its biological function in this setting. 
Figure 7
Model for FRAT and TMEM98 interaction Schematic representation of possible TMEM98 topologies and trafficking activities based on in silico prediction algorithms and our experimental data. Given that most algorithms predict TMEM98 to be a single-pass transmembrane protein and our data confirm that the C-terminus of the protein is located on the extracellular surface, model A (left) is the most likely scenario. However, it would require TMEM98 and FRAT to interact in the endosomal compartment, for which no evidence is available to date. The alternative model B (right) assumes the presence of a second transmembrane domain, to allow exposure of a cytosolic FRAT-binding domain. Depiction of the endosomal trafficking and sorting compartments is based on the previously reported association of different Rab proteins with specific endosomal domains .
van der Wal et al., Figure 7 Model 
Materials and Methods
Yeast two-hybrid screening
Full-length murine Frat2 (encoding amino acids 1-232) or a deletion mutant starting at an internal SmaI site (Frat2DN, encoding amino acids 139-232) were cloned in a LexA Cterminal fusion vector provided by Hybrigenics. Constructs were confirmed to be in frame by sequencing the inserts.
Yeast two-hybrid (Y2H) screening was performed by Hybrigenics, S.A., Paris, France (http://www.hybrigenics.com). Shortly, the bait construct was transformed in the L40 GAL4 yeast strain . A Human fetal brain random-primed cDNA library, transformed into the Y187 yeast strain and containing ten million independent fragments, was used for mating. The screen was first performed on a small scale to adapt the selective pressure to the intrinsic property of the bait. For full-length Frat2, no auto-activation of the bait was observed. The Frat2DN bait was found to auto-activate the Y2H system, and 50mM 3-aminotriazole was found to be the optimal concentration to reduce background colonies. Next, the full-scale screen was performed in conditions ensuring a minimum of 50 million interactions tested, in order to cover five times the primary complexity of the yeasttransformed cDNA library . A total of 95 million (Frat2 screen) and 87 million (Frat2DN screen) interactions were actually tested. After selection on medium lacking leucine, tryptophane, and histidine, 8 and 141 positive clones were picked for Frat2 and Frat2DN, respectively, and the corresponding prey fragments were amplified by PCR and sequenced at their 5' and 3' junctions.
Sequences were then filtered as described previously ) and compared to the latest release of the GenBank database using BLASTN . A Predicted Biological Score (PBS) was assigned to assess the reliability of each interaction . First, a local score takes into account the redundancy and independency of prey fragments, as well as the distributions of reading frames and stop codons in overlapping fragments. Second, a global score takes into account the interactions found in all the screens performed at Hybrigenics using the same library. In addition, potential false-positives are flagged by a specific "E" PBS score. This is done by discriminating prey proteins containing "highly connected" domains, previously found several times in screens performed on libraries derived from the same organism. Raw data of the yeast-two-hybrid screen are available at http://dx.doi.org/10.17605/OSF.IO/EF74W.
DNA constructs
The pGlomyc-Frat1 and pGlomyc-Frat2 plasmids were described previously . The full-length coding sequence of murine Tmem98 was amplified from a mix of murine embryonic and keratinocyte cDNA using forward 5'-AAAAAGCTTGCCATGGAGACTGTGGTGAT CGTC-3' and reverse 5'-TTTTGAATTCTTAAATGGCCGACTGTTCCT GCAGGAAGC-3' primers and cloned into pSP72 (Promega) as a HindIII/EcoRI fragment. A FLAG tag was inserted at the C-terminus via a PstI/EcoRI restriction digest. The Tmem98-FLAG cassette was cloned into pCDNA3.1 as a HindIII/HindIII fragment. The deletion mutant Tmem98DN-FLAG was generated by deleting the first 34 amino acids using an internal XhoI site. A slightly modified construct, in which a stretch of superfluous amino acids was removed by insertion of a HindIII/EcoRI oligomer behind the C-terminus of Tmem98, was used for most of the experiments.
A Tmem98-AcGFP fusion construct was generated by cloning the Tmem98 coding sequence into the SmaI cut pAc-GFP1-N2 vector (Clontech). TMEM98-AcGFP did not inhibit FRAT2 activity to a similar extent as TMEM98-FLAG (data not shown). Because AcGFP has the tendency to dimerize , we later replaced this construct with Tmem98-SGFP2. Because GFP is not fluorescent at lower pH, we also generated Tmem98-mTurquoise2 and Tmem98-mCherry fusions. This was achieved by exchanging AcGFP1 with either sGFP2, mTurquoise2 (mTq2) or mCherry fragments using a BamHI/BsrGI digest.
Tmem98 knockdown constructs were generated by annealing sense and antisense oligo's and cloning the annealed products into pRetrosuper (a gift from Dr. Thijn Brummelkamp, Netherlands Cancer Institute). Knockdown constructs recognize both mouse Tmem98 and human TMEM98 based on sequence homology. Sense oligo sequences: 5'-GATCCCCCTGGAAGCATGGAGACTGTTTC AAGAGAACAGTCTCCATGCTTCCAGTTTTT GGAAA-3' (RNAi1), 5'-GATCCCCCCATCTTGAAGATTTGTCATTCA AGAGATGACAAATCTTCAAGATGGTTTTTG GAAA-3' (RNAi2) and 5'-GATCCCCACATCATTGTGGTGGCCAATTCA AGAGATTGGCCACCACAATGATGTTTTTTG GAAA-3' (RNAi3).
Additional constructs used were Lck-mCherry, Rab7-mCherry and Lamp1-mCherry (a gift from Dr. Joachim Goedhart, University of Amsterdam);
Rab9a-mCherry (Addgene plasmid #78592, donating investigator Yihong Ye ), pLenti-CMV-rtTA3 Hygro (Addgene plasmid #26730, donating investigator Eric Campeau), pTREtight2 (Addgene plasmid #19407, donating investigator Markus Ralser), CMV-Renilla (Promega) and MegaTOPFLASH (a gift from Dr. Christophe Fuerer and Dr. Roel Nusse, Stanford University).
To create a stable doxycycline-inducible TMEM98-FLAG cell line, Tmem98-FLAG was amplified by PCR from pCDNA3.1-Tmem98-FLAG and inserted into pTREtight2 as an EcoRI/EcoRI fragment. All constructs were verified by restriction enzyme digestion analysis and Sanger sequencing prior to use.
The pGlomyc-Frat1, -FLAG constructs will be made available via Addgene.
Cell culture and transfection
HEK293TN, HEK293A and HeLa cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (Gibco) under 5% CO2 at 37°C in humidifying conditions. On the day prior to transfection, cells were plated in 6-well tissue culture plates, 12well tissue culture plates, or 8-well chamber slides. Cells were transfected with a total amount of 200 ng (per 8-chamber slide), 500 ng (for 12-well plates) or 1500 ng (for 6-well plates) DNA per well using polyethylenimine (PEI, Polysciences Inc., dissolved at 1 mg/ml in ethanol). Transfection mixtures were made in Optimem using a 1:3 ratio (µg:µl) of DNA and PEI. In all cases, empty pGlomyc vector was added to control for the total amount of DNA transfected. Master mixes were made where possible to reduce variation.
To generate a stable doxycycline inducible TMEM98-FLAG cell line, HEK293TN cells were transfected with the pTREtight2-Tmem98-FLAG and pLenti-CMV-rtTA3-Hygro constructs. Following hygromycin selection, individual clones were picked and tested for TMEM98 induction by Western blot analysis. FACS analysis revealed that even within a clonal population of cells, not all cells induced TMEM98-FLAG expression, Subcloning did not solve this problem, suggesting that some cells had either lost or randomly silenced the construct.
Where indicated, cells were treated with MG132 (Sigma-Aldrich), bafilomcycin (Sigma-Aldrich) or Brefeldin A (Sigma Aldrich) for the times mentioned.
Protein gels and Western blot analysis
HEK293TN cells transfected as described above with the indicated constructs were harvested 48 hours post-transfection by lysis in RIPA buffer supplemented with protease inhibitors (Roche) or in passive lysis buffer (Promega).
Protein concentration was determined using a colorimetric assay (BioRad) or Pierce BCA protein assay (Thermo Scientific).
For immunoprecipitation, HEK293TN cells were transfected in a 6-well plate. Protein lysates were incubated at 4°C with a mouse monoclonal antibody directed against the FLAG-tag (M2, Stratagene). Immunocomplexes were pulled down by incubation with protein G sepharose, after which samples were washed in RIPA buffer to remove unbound protein, resuspended in RIPA buffer, run on precast protein gels (either 10% or 4%-12%, Nupage) and analyzed on Western blot. Equal amounts of protein were prepared in passive lysis buffer with protein loading buffer (125 mM Tris-HCl (pH 6.8), 50% glycerol, 4% SDS, 0.2% Orange-G, 10% betamercaptoethanol) and samples were boiled at 95˙C prior to loading.
For the Western blots that gave rise to Figure 4B -C and Figure 5C , samples were run on 12% SDS-PAGE gel in electrophoresis buffer (25 mM Tris base, 192 mM Glycine, 0.1% SDS) at 80-120V and transferred to 0.2 µm nitrocellulose membrane (Biorad) overnight at 30V. Membranes were blocked in 1:1 TBS:Odyssey Blocking buffer (LI-COR) and incubated overnight at 4˙C with primary antibodies (rabbit anti-TMEM98, Proteintech, 1:1000; rabbit anti-FLAG polyclonal, Sigma, 1:2000; mouse anti-FLAG monoclonal M2, Stratagene 1:2000, mouse anti-myc monoclonal 9E10, Invitrogen, 1:5000; mouse anti-myc monoclonal 9B11, Cell Signaling Technologies, 1:1000; mouse anti-tubulin, Sigma-Aldrich, 1:1000; mouse anti-Hsp90a/b, mouse, Santa-Cruz, 1:1000, mouse anti-GSK3b, BD Transduction labs, 1:2000) in TBS:Odyssey Blocking buffer supplemented with 0.1% Tween-20. Secondary antibody (antimouse 680, LI-COR, 1:20,000; anti-rabbit 800, LI-COR, 1:20,000) incubation was performed in TBS-T for 45 minutes at room temperature. Membranes were stored at 4˙C in TBS and imaged on an Odyssey Fc (LI-COR) for two minutes at 680 nm and 800 nm. For the Western blots depicted in Figure 1B, 2E, 3C , 4A-B, 5A-B and D, samples were run on precast protein gels (either 10% or 4%-12%, Nupage) and blots were imaged using ECL detection (Pierce) instead, after labelling with goat-antimouse-HRP and goat-anti-rabbit-HRP secondary antibodies. These blots were not used for quantification, since it could not be excluded that some of the signal on the film could be oversaturated.
Luciferase assay
For luciferase assay experiments, triplicate transfections were performed in 12-well plates. For each well, HEK293TN cells were transfected with 500 ng DNA total (usually 100 ng MegaTOPFLASH, 50 ng CMV-Renilla and different amounts (25, 50, 100, 200 ng) of myc-Frat2 and Tmem98 constructs as required, supplemented with empty pGlomyc vector as carrier DNA. Cells were harvested 48 hours post-transfection in passive lysis buffer (Promega) and analysed with by dual luciferase assay in a Lumat LB 9507 Luminometer (Berthold Technologies) or a GloMax navigator (Promega). For each technical replicate, 10 µl of lysate was transferred to a black 96-well Optiplate using 50 µl of Firefly and 50 µl of Renilla detection reagents (reagents were either from Promega or home-made, according to a protocol shared by Dr. Christophe Fuerer). The ratio of Firefly:Renilla values was used as a measure of TOPFLASH activation. Within each experiment, all data were normalized to empty pGlomyc transfected cells, the Firefly:Renilla ratio of which was set to 1. Experiments were performed at least three times. For Western blot analyses of luciferase assay experiments, the lysates from triplicate wells were pooled after the luciferase assay measurements were performed.
FACS analysis
A stable, doxycycline-inducible, clonal tetO-Tmem98/CMV-rtTA3 HEK293TN cell line was treated with doxycycline (1 µg/ml) for 24 hours to induce TMEM98-FLAG expression. Vehicle treated cells were taken along as a negative control. Cells were then washed with PBS, trypsinized, and resuspended in HBSS/5%FCS. A small aliquot was taken as an unfixed, unstained control sample. For extracellular staining, unfixed cells were stained with an anti-FLAG M2 antibody (1:100, Sigma) on ice for 20 minutes, followed by labelling with a secondary antibody Donkey-anti-Mouse Alexa 488 (1:500, Molecular Probes) on ice for 20 minutes. For total intracellular and extracellular staining, cells were dissolved in 100 ul of Fixation/Permeabilization buffer A (BD Biosciences) and incubated at room temperature for 15 minutes. Following a wash with HBSS/5%FCS, cells were incubated with 100 ul Permeabilization buffer B (BD Biosciences) prior to staining with the anti-FLAG and Donkey/Mouse Alexa488 antibodies as described above. Cells were then washed in HBSS/5% FCS, dissolved in 400 ul HBSS/5% FCS and analysed on a BD FACS AriaIII.
Confocal microscopy
For immunofluorescence analysis, cells were plated in 8-well chamber slides and transfected on either the same day or the following day with a total amount of 200 ng (per 8-chamber slide) DNA using PEI. For direct fluorescent detection of fluorescent fusion proteins, cells were seeded onto glass coverslips in a 6 well plate and transfected with a total amount of 500 ng DNA per well.
Cells were imaged at 48 hours after transfection. The experiments depicted in figure 2A, 6B and 6C were performed on live cells in microscopy medium (20 mM HEPES, pH 7.4; 137 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.8 mM MgCl2, 20 mM glucose). Lysotracker red (Invitrogen) was added 5-15 minutes prior to analysis. For all other imaging experiments, cells were fixed in 4% paraformaldehyde or icecold methanol. For fluorescent protein detection, cells were washed in PBS and mounted in Mowiol mounting medium. For immunofluorescence staining, cells were permeabilized with 0.2% Triton-X100 or 0.1% Saponin and stained with antibodies directed against the FLAG tag (M2, Sigma, 1:400), Golgin97 (CDF4, Molecular Probes, 1:100), EEA1 (BD Biosciences, 1:100-1:200) and MPR (1:100-1:200). Nuclei were counterstained with TOPRO3 or DAPI. Secondary antibodies were Alexa conjugated Goat-anti-Mouse, Donkeyanti-Mouse or Goat-anti-Rabbit antibodies with Alexa 488, 568 or 633 dyes. Samples were imaged by sequential scanning on a Leica SP2 or SP8, or a Nikon A1 confocal microscope, using 405nm, 457nm, 488nm, 561nm and 633nm lasers and appropriate filter blocks or AOBS settings.
Software, in silico analysis and online repositories
Image studio Lite (LI-COR) was used for quantitative Western blot analysis. Luciferase experiments were analysed in Excel. Graphs were made in GraphPad Prism and R Studio. FACS data were analysed with FlowJo software.
Confocal microscopy images were processed in Fiji. Overlays were made using the Image5D plugin, using green and magenta for dual channel overlays. For single channel images, appropriate LUTs were selected for contrast and visualization purposes. Figures were made in Adobe Illustrator.
Online topology prediction algorithms (HMMTOP; Phobius; TMHMM; TMpred; DAS-TMfilter, PrediSi, SignalP 4.1, WOLF PSORT, PredictProtein, SherLoc2, Secretome 2.0) were used to predict the TMEM98 topology (Table 3, 4) .
Multiple sequence alignments were made at https://www.ebi.ac.uk using data extracted from the Ensembl genome database (https://www.ensembl.org) as input (Figure 1 and Supplementary Figure 1, 2) . Version 3.4 of the BioGRID protein-protein interaction database was accessed on 9 June 2018 at https://thebiogrid.org ( Supplementary Figure 4) . Evolutionary Conserved Regions in human TMEM98 (Figure 1 and Supplementary Figure  1) were determined using the Aminode Evolutionary Analysis tool available at http://www.aminode.org. . The LIFEdb database (Bannasch et al., 2004; was accessed at https://www.dkfz.de/en/mga/Groups/LIFEdb-Database.html to find images depicting the subcellular localization of N-terminal and Cterminal TMEM98 fusions ( Supplementary  Figure 3) . Supplementary Figure 1 Evolutionary conservation of TMEM98 (A) Amino acid alignment of TMEM98 orthologues from 14 vertebrate species. Conserved amino acids are highlighted in blue. The region highlighted in pink is predicted to have structural homology to the GCIP domain (PFAM PF13324) found in the Grap2 and cyclin-D-interacting protein.
Supplementary Figures
(B) Plot highlighting the Evolutionary Conserved Regions (yellow bars on top) and amino acid substation rate (red line). The human TMEM98 protein sequence (amino acids 1-226) reads from left to right. Plot generated at http://www.aminode.org. (C) Amino acid alignment of TMEM98 orthologues in human, mouse and chicken, revealing a high degree of homology throughout. Topology prediction programs indicate a potential signal sequence or N-terminal transmembrane region (TM1) and a putative second transmembrane region (TM2) around position 161-172. Green shading indicates the relative overlap between different prediction algorithms, with the most intense shading highlighting the core of the potential transmembrane domains. The underlined region indicates the shortest TMEM98 clone picked up the yeast-two-hybrid screen. The domain that is predicted to have structural homology to the GCIP domain is again highlighted in pink. ELELDDVVITNPHIEAILENEDWIEDASGLMSHCIAILKICHTLTEKLVAMTMGSGAKMK 120 :***************:**:******. ::
. : ************: * Xenopus  GGMDWIDQSLSAAEDHLAVLREAALATEPERPMSGADNFLQEQSTI 226  Coelacanth  GGLDWIDQSLSAAEEHMIVLREAALASESDRTLAGAEGFCQEQSAI 226  Opossum  GGLDWIDQSLSAAEEHMEVLREAALASEPERGLLGAEGFLQEQSAI 226  Tasmanian_devil  GGLDWIDQSLSAAEEHLEVLREAALASEPERGLPGAEGFLQEQSAI 226  Rabbit  GGLDWIDQSLSAAEEHLEVLREAALASEPEKVLAGPEGFLQEQSAI 226  Rat  GGLDWIDQSLSAAEEHLEVLREAALASEPDKSLPNPEGFLQEQSAI 226  Mouse  GGLDWIDQSLSAAEEHLEVLREAALASEPDKSLPNPEGFLQEQSAI 226  Human  GGLDWIDQSLSAAEEHLEVLREAALASEPDKGLPGPEGFLQEQSAI 226  Chimpanzee  GGLDWIDQSLSAAEEHLEVLREAALASEPDKGLPGPEGFLQEQSAI 226  Orangutan  GGLDWIDQSLSAAEEHLEVLREAALASEPDKGLPGPEGFLQEQSAI Van der Wal et al., Supplementary Figure 1 A B hsTMEM98  TSASVSDIIVVAKRISPRVDDVVKSMYPPLDPKLLDARTTALLLSVSHLVLVTRNACHLT 180  Y2H_FRAT2_clone_1  TSASVSDIIVVAKRISPRVDDVVKSMYPPLDPKLLDARTTALLLSVSHLVLVTRNACHLT  Y2H_FRAT2_clone_2  TSASVSDIIVVAKRISPRVDDVVKSMYPPLDPKLLDARTTALLLSVSHLVLVTRNACHLT  Y2H_FRAT2_clone_3  TSASVSDIIVVAKRISPRVDDVVKSMYPPLDPKLLDARTTALLLSVSHLVLVTRNACHLT  Y2H_FRAT2_clone_4  TSASVSDIIVVAKRISPRVDDVVKSMYPPLDPKLLDARTTALLLSVSHLVLVTRNACHLT  Y2H_FRAT2_clone_5 TSASVSDIIVVAKRISPRVDDVVKSMYPPLDPKLLDARTTALLLSVSHLVLVTRNACHLT Y2H_FRAT2ΔN_clone_1 TSASVSDIIVVAKRISPRVDDVVKSMYPPLDPKLLDARTTALLLSVSHLVLVTRNACHLT Y2H_FRAT2ΔN_clone_2 TSASVSDIIVVAKRISPRVDDVVKSMYPPLDPKLLDARTTALLLSVSHLVLVTRNACHLT Y2H_FRAT2ΔN_clone_3 TSASVSDIIVVAKRISPRVDDVVKSMYPPLDPKLLDARTTALLLSVSHLVLVTRNACHLT Y2H_FRAT2ΔN_clone_4 TSASVSDIIVVAKRISPRVDDVVKSMYPPLDPKLLDARTTALLLSVSHLVLVTRNACHLT Y2H_FRAT2ΔN_clone_5 TSASVSDIIVVAKRISPRVDDVVKSMYPPLDPKLLDARTTALLLSVSHLVLVTRNACHLT ************************************************************ hsTMEM98 GGLDWIDQSLSAAEEHLEVLREAALASEPDKGLPGPEGFLQEQSAI 226 MPCRREEEEEAGDEAEGEEDDDSFLLLQQSVTLGGSTDVDRLIVQIGETLQLDTAHDRPA 60
GRSAPYCVAEIAPGASALPGPGRRGWLPGSVASHRIQQRRWTAGGARAADDDPHRLLQQL 180 
Supplementary Figure 8 Putative interactors of TMEM98
Network of potential TMEM98 interaction partners, obtained via https://thebiogrid.org, a publicly available repository for interaction datasets. Interactions were detected by either two-hybrid screening or affinity capture mass spectrometry. TMEM98 is not degraded by the lysosome Western blot of lysates from HEK293T cells stably transfected with tetO-TMEM98-FLAG and CMV-rtTA3. TMEM98-FLAG expression was induced by growing cells in the presence of doxycycline (DOX, 1 mg/ml). Cells were then chased in the presence of cycloheximide (CHX) to block new protein synthesis for the indicated timepoints, allowing TMEM98 decay to be visualized. Co-treatment of the cells with the proteasome inhibitor MG132, but not the lysosome inhibitor bafilomycin (BAF) partially prevents TMEM98-FLAG breakdown. van der Wal et al., Supplementary Figure 9 0 2 4 6 0 2 4 6 0 2 4 6 hours of treatment CHX CHX + BAF CHX + MG132 HSP90 TMEM98-FLAG
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